Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL4093450 | 0.89 | HSD17B10 (0.42) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL13365218 | 0.87 | ACHE (0.44) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL9812457 | 0.85 | KDM4E (0.57) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL3913401 | 0.83 | ERN1 (0.41) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL4093452 | 0.82 | TSHR (0.37) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL1965439 | 0.80 | HPGD (0.48) | HSD17B10TSHRCYP3A4RECQLALDH1A1 | |
| SCHEMBL70208 | 0.80 | HSD17B10 (0.55) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL7885118 | 0.80 | HSD17B10 (0.55) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL2927011 | 0.79 | HSD17B10 (0.48) | HSD17B10TSHRCYP3A4RECQLTTR | |
| SCHEMBL4825263 | 0.79 | TRPV1 (0.49) | HSD17B10TSHRTHRBALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577236-B2 | Processes for preparation of Tezacaftor | LAURUS LABS LIMITED (IN) | 2026-03-17 | — | — | US | disclosed |
| CN-119913563-A | PtZn-ZnOx interface active site-rich catalyst for low-potential benzoic acid production, and preparation method and application thereof | 华南理工大学 | 2025-05-02 | — | — | CN | disclosed |
| US-20250044700-A1 | PATTERN FORMING METHOD AND METHOD FOR PRODUCING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2025-02-06 | — | — | US | disclosed |
| WO-2024254923-A1 | POLYMER FOR PHOTOETCHING MEDIUM COMPOSITION, AND PHOTOETCHING MEDIUM COMPOSITION | 嘉庚创新实验室 | 2024-12-19 | — | — | WO | disclosed |
| CN-115975561-B | E (E)NFPreparation method of graded lignan-based wood adhesive | 中国林业科学研究院林产化学工业研究所 | 2024-12-17 | — | — | CN | disclosed |
| EP-4405097-B1 | VPO CATALYST HAVING IMPROVED SELECTIVITY AND STABILITY AND METHOD FOR THE PREPARATION THEREOF | CLARIANT INT LTD (CH) | 2024-11-20 | — | — | EP | disclosed |
| CN-118957652-A | Nickel-based bimetallic phosphide catalyst and preparation method and application thereof | 中国地质大学（武汉） | 2024-11-15 | — | — | CN | disclosed |
| CN-118420442-B | Method for preparing vanillin by reducing vanillin with silicon powder | 天津市职业大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-118420442-A | Method for preparing vanillin by reducing vanillin with silicon powder | 天津市职业大学 | 2024-08-02 | — | — | CN | disclosed |
| EP-4405097-A1 | VPO CATALYST HAVING IMPROVED SELECTIVITY AND STABILITY AND METHOD FOR THE PREPARATION THEREOF | Clariant International Ltd (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-5183810-A | Hyptoensive agents | MERCK & CO., INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0517812-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0515548-A1 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0515535-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| WO-1991012002-A1 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| US-4923885-A | PSORIASIS, GASTROINTESTINAL DISORDERS, SKIN DISORDERS; ANTICARCINOGENIC, ANTITUMOR, AND ANTIGROWTH AGENTS | MERCK & CO., INC. (US) | 1990-05-08 | — | — | US | disclosed |
| US-4525304-A | Process for preparing oxazolinoazetidinones | ELI LILLY AND COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0109817-A2 | Process for preparing oxazolinoazetidinones | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577236-B2 | Processes for preparation of Tezacaftor | CYP4A11, F9, CYP3A4 | HSD17B10 912/4885TSHR 34/4885CYP3A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.